Provided are peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. Provided are also tumor-associated cytotoxic T cell (CTL) peptide epitopes that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. Provided are several peptide sequences derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
